BMO Capital Raises Chemours Price Target Following Taiwan Site Sale
BMO Capital analyst John McNulty increased Chemours' price target to $20 from $18, maintaining an Outperform rating after the company sold its Taiwan TiO2 site for $360 million.
Topic
Latest reporting and analysis tagged with Chemours.
BMO Capital analyst John McNulty increased Chemours' price target to $20 from $18, maintaining an Outperform rating after the company sold its Taiwan TiO2 site for $360 million.